[Effects of improved levels of plasma bicarbonates in terminal renal failure]. / Effets de l'amélioration du taux des bicarbonates plasmatiques chez l'insuffisant rénal terminal.

Correction of chronic renal acidosis was attempted for 6 weeks in 20 end stage renal failure patients on chronic acetate hemodialysis by means of 6-9 g of sodium bicarbonate given orally by means of gastric juice resistant capsule of 1 g. Normalisation of the inter-dialysis acid base status was obtained without major side effects.

[Unusual therapeutic problems posed by acute kidney failure. Importance of bicarbonate dialysis]. / Les problèmes thérapeutiques particuliers posés par l'insuffisance rénale aiguë. Intérêt de la dialyse au bicarbonate.

The severity of acute renal failure is linked to the associated multiple visceral failures. These failures represent therapeutical challenges that the authors discuss on the basis of their experience of the last 10 years 7 of which being based on the use of bicarbonate dialysis.

Comparison of ethinylestradiol and mestranol in sequential-type oral contraceptives in their effects on blood glucose and serum insulin in oral glucose tolerance tests.

Forty 3-hour oral glucose tolerance tests (OGTTs) were performed in 10 assumedly healthy female volunteers 19 to 30 years old, each serving four times as her own control. Each subject was taking a sequential type oral contraceptive containing either 50 microgram of ethinylestradiol or 80 microgram of mestranol alternatingly in four consecutive treatment cycles. The OGTTs were performed on the 6th day of each cycle, during pure estrogen medication. Blood glucose and serum insulin values did not differ significantly under either estrogen as tested by the t-test for paired observations. Our results do not support the findings of others that mestranol has a more pronounced or even exclusively adverse effect on glucose tolerance as compared with ethinylestradiol.

PIP: 10 female volunteers (19-30 years) received ethinyl estradiol (EE) and mestranol (ME) in order to determine whether treatment would influence carbohydrate metabolism. EE dose was 50 mcg and ME dose was 80 mcg. In each treatment cycle the estrogenic compound was given for 7 days, followed by 15 days of combined treatment with a gestagenic compound and a treatment-free interval of 6 days during which withdrawal bleeding occurred. On the 6th day of each treatment cycle on oral glucose tolerance test (OGTT) was performed. Blood smaples were obtained every 30 minutes over 3 hours and assayed for blood glucose and for serum insulin. The differences in blood glucose levels or serum insulin between EE cycles and ME cycles were insignificant.